Document is current
Any future updates will be listed below
-
Authors
Elliott, Kerryn https://orcid.org/0000-0001-9238-7879
Singh, Vinod Kumar https://orcid.org/0000-0002-7556-2505
Bäckerholm, Alan https://orcid.org/0000-0002-8590-1195
Ögren, Linnea https://orcid.org/0009-0002-1836-6660
Lindberg, Markus https://orcid.org/0000-0001-8984-8064
Soczek, Katarzyna M.
Hoberg, Emily
Luijts, Tom https://orcid.org/0000-0002-0231-3815
Van den Eynden, Jimmy
Falkenberg, Maria
Doudna, Jennifer https://orcid.org/0000-0001-9161-999X
Ståhlberg, Anders https://orcid.org/0000-0003-4243-0191
Larsson, Erik https://orcid.org/0000-0003-1400-0119
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Vetenskapsrådet
Cancerfonden
- License Information
-
More Information
Article History
Received: 4 June 2024
Accepted: 31 October 2024
First Online: 18 November 2024
Competing interests
: A.S. is a co-inventor of the SiMSen-Seq technology that is patent protected (U.S. Serial No.:15/552,618). A.S. declares stock ownership in Tulebovaasta, Iscaff Pharma and SiMSen Diagnostics, and is a board member of Tulebovaasta. The other authors declare no competing interests.
